Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attackYuan Fang, Ying–Hong Shi, Weiren Liu et al.|Hepatology|2022Cited by 158
A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinomaXi‐Fei Jiang, Ying–Hong Shi, Congying Pu et al.|Cell Discovery|2023Cited by 52
Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective studyGuiqi Zhu, Ying–Hong Shi, Weiren Liu et al.|Molecular Oncology|2021Cited by 44
Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogrammingHan Wang, Ying–Hong Shi, Fangming Liu et al.|Experimental Cell Research|2024Cited by 44
Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapyJun Gao, Ying–Hong Shi, Yuan Fang et al.|Oncogene|2023Cited by 44